NEW TARGETS
Until very recently, the understanding and availability of drug targets in Alzheimer’s has been sparse and concentrated on acetylcholinesterase, NMDA receptors or insoluble amyloid plaque. Cognition Therapeutics has taken a new approach, using the new concept that soluble Abeta oligomers are the primary neurotoxic element causing neuronal degeneration and cognitive decline in Alzheimer’s disease and discovered a brand new drug target, the sigma-2/PGRMC1 receptor.
Learn More
NEW DRUGS
The therapeutic standards of care for Alzheimer’s only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Abeta oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.
Learn More
NEW HOPE
Very recent clinical advances using Abeta monoclonal antibodies that interact with both soluble Abeta oligomers and insoluble fibrillar ABeta, have demonstrated a reduction in Abeta burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Abeta approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.
Learn MoreLatest News
New Math For High Growth Companies Requires Angel Syndication – Forbes
September 25, 2015. If you’re an angel investor and aren’t yet well-versed in syndication, now is the time to take notice. The changing math required to fund promising companies explains why: the median deal
US biotech Cognition Therapeutics tests Alzheimer’s drug in Australia
The Australian, September, 18, 2015. Australia’s neuroscience expertise has convinced US company Cognition Therapeutics to launch a clinical study of a new Alzheimer’s drug in Melbourne, backed by a local
Cognition Therapeutics Commences Clinical Trials in Melbourne
Scale Angels investee company Cognition Therapeutics commences clinical trials in Melbourne Friday 18th September 2015. Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on
Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing
PITTSBURGH, Sept. 8, 2015 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s